Eli Lilly Reports Strong Third Quarter Results Driven by GLP-1 Growth and Raises Full-Year Guidance
Eli Lilly (LLY) delivered a robust third-quarter performance, characterized by a 39% year-over-year revenue increase to $24.4 billion. The growth was primarily propelled by its GLP-1 portfolio, specifically Mounjaro sales rising 65% to $10.7 billion and Zepbound sales increasing 49% to $5.4 billion. Despite lower net realized prices for these therapies, significant volume growth successfully offset the pricing pressure. Beyond weight loss and diabetes treatments, the company saw strong performance from Kisunla (Alzheimer's), Ebglyss (eczema), and Jaypirca (cancer). Following these results, Eli Lilly raised its full-year 2026 revenue guidance to a range of $91 billion to $92 billion. While competition in the GLP-1 market is expected to intensify, the company's current momentum suggests continued dominance in the sector.
Tickers: $LLY
Topics: Diabetes therapy GLP-1 drugs Pharmaceuticals Quarterly earnings Weight loss drugs